A Model of Intratumor and Interpatient Heterogeneity Explains Clinical Trials of Curative Combination Therapy for Lymphoma.

ABSTRACT:

Significance

A new model of intratumor and interpatient heterogeneity in response to drug combinations explains and predicts the results of clinical trials of curative-intent treatments for DLBCL. This model can be used to understand and inform optimal design of curative drug combinations and clinical trials. See related commentary by Goldstein et al., p. 153.

SUBMITTER: Pomeroy AE 

PROVIDER: S-EPMC12050944 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature